antimalarial agent-14

Antimalarial agent 14 (NSC-102533) is a bioactive chemical.

Antimalarial agent 13 (N2-(3-chlorophenyl)-N4-(furan-2-ylmethyl)quinazoline-2,4-diamine) is a potent antimalarial agent.

Antimalarial agent 30 has anti-Plasmodium berghei liver stage parasite activity and antimalarial activity for the study of malarial infections.

Antimalarial agent 33 (compound 5g) exhibits antiplasmodial activity targeting both erythrocytic and hepatic stages of Plasmodium, with an effective concentration (EC50) of 1.1 μM against the K1 strain of P. falciparum. It demonstrates improved microsomal stability with a half-life (T1/2) of 29 minutes and displays no significant cytotoxicity against primary hepatocytes [1].

Kaempferol glycoside, known as Antioxidant agent-14, has been isolated from the leaves of Brassica juncea [1].

Antimalarial agent 1 is an effective antimalarial agent.

Compound 24 (Compound 7), an in vitro antimalarial agent, demonstrates inhibitory activity against the Plasmodium falciparum W2 strain with an IC50 of 0.81 μM and exhibits a cytotoxicity threshold (CC50) exceeding 200 μM in HepG2 cells [1].

Antimalarial agent 28 (Compound 2i) acts as an antiplasmodial agent, exhibiting inhibition of P. berghei with IC50 values of 0.561 μM for the liver stage, 0.14 μM for early gametocytes, and 4.34 μM for the ring stages of P. falciparum [1].

Compound 29 (also known as Compound 16) is an antimalarial agent that demonstrates inhibition of the P. berghei liver stage parasite load, exhibiting an effective concentration (EC50) of 5.2 μM [1].

Antimalarial agent 15 is a parasite inhibitor that exhibits antimalarial effects and inhibits the growth of Plasmodium falciparum 3D7 with an IC50 value of 20 nM.

Antimicrobial agent-14 is a benzyl thiophene sulfonamide derivative that is often used as an antimicrobial agent.Antimicrobial agent-14 has a MIC value of 200 μM against Campylobacter coli ATCC33559, which can be used to study bacterial foodborne gastroenteritis.

Antiparasitic Agent-14 is a potent antiparasitic compound with demonstrated cytotoxicity and antiparasitic activity, effectively inhibiting the growth of trypomastigote and amastigote forms [1].

Antimalarial agent 9 is an effective antimalarial agent, a quinoline-imidazole derivative compound. antimalarial agent 9 showed significant in vitro antimalarial effects against CQ-susceptible strains (IC50-0.14 μM) and MDR strains (IC50-0.41 μM), with minimal cytotoxicity and high selectivity.

Antiviral agent 14 is an antiviral agent that inhibits tobacco mosaic virus (TMV) (EC50: 135.5 μg/mL), and cucumber mosaic virus (CMV) (EC50: 178.6 μg/mL).

Antimalarial agent 26, a derivative of 1,4-naphthoquinones, demonstrates antimalarial properties through oral administration. It exhibits cytotoxic effects on P. falciparum while maintaining selectivity against mammalian cell lines and effectively inhibits P. berghei-induced parasitemia in vivo [1].

Compound 31 (compound 7k) is an orally active inhibitor of Plasmodium falciparum aspartic protease, plasmepsin X (PMX), with antimalarial properties [1].

Antimalarial agent 8 (Compound 7e) is a novel, orally active antimalarial agent that is effective against P. falciparum in vitro and effective orally in an in vivo mouse model of malaria (40 mg/kg).

Anticancer agent 14 is a lead compound (IC50: 0.20-0.65 μM) that blocks the cell cycle of breast cancer cells, induces apoptosis and causes loss of mitochondrial membrane potential.

Antimalarial agent 2 is an orally active, novel antimalarial agent that exhibits rapid in vitro killing effects.

Antifungal agent 14 demonstrates potent broad-spectrum antifungal activity, effectively targeting a variety of fungal strains with exceptional minimum inhibitory concentration values.

Antimalarial agent 7 is a potent and effective inhibitor of PfATP4. Antimalarial agent 7 has potential for the study of the human plasmodium falciparum.

Antimalarial agent 27 (compound 11a) potently inhibits P. falciparum with an IC50 of 0.37 μM and targets the parasite's 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) enzyme with an IC50 of 0.11 μM, indicating its mechanism of action [1].

Antimalarial agent 20, exhibiting potent efficacy with an IC50 value of 0.6 nM against the P. falciparum NF54 parasite strain within the NF54 albumax assay, serves as a significant antimalarial compound.

Antimalarial agent 10 (Compound 17b) is an amino alcohol-quinoline compound. Antimalarial agent 10 is also an antimalarial agent capable of acting on Pf3D7 (IC50: 14.9 nM) and PfW2 (IC50: 11 nM) with a selectivity index greater than 770 regardless of the cell line.

Antitubercular agent-14 (Compound 1) shows antitubercular activity. The MIC value of Antitubercular agent-14 against M. tuberculosis is 0.3 μg/mL [1].

Antimalarial agent 3, an antimalarial agent, exhibits potent activity against Plasmodium with an IC50 of 0.035 μM. Furthermore, it demonstrates an exceptionally high selectivity index in relation to mammalian cells.

Antitrypanosomal agent 14 (Compound 1), a potent T. brucei inhibitor with an effective concentration (EC50) of 0.47 μM, also inhibits Tb GSK3 with an inhibitory concentration (IC50) of 12 μM, and is utilized in the research of Human African Trypanosomiasis [1].

Antimalarial agent 12 is an effective antimalarial agent that inhibits the growth of Plasmodium falciparum strains Dd2 and 3D7 with EC50 values of 155 nM and 136 nM, respectively. antimalarial agent 12 has a MIC >250,000 nM against E. coli and also acts on Antimalarial agent 12 has a MIC of >250,000 nM against E. coli and also works on HEK-293 and hPHep cell lines with CC50 values of 10,000-50,000 nM.

Antimalarial agent 23, a benzimidazole-based compound, exhibits potent antimalarial activity, demonstrated by its low IC50 values of 0.08 μM for PfNF54 and 0.10 μM for PfK1, respectively. This compound effectively inhibits β-hematin formation, yet it does not directly interfere with the conversion of heme to hemozoin [1].

Antimalarial agent 17, functioning both as an antimalarial agent and a herbicide, inhibits photosystem II and demonstrates post-emergence herbicidal efficacy comparable to commercial herbicides [1].

Antimalarial agent 16 is a parasite inhibitor that exhibits antimalarial effects and inhibits the growth of Plasmodium falciparum with an IC50 value of 2.0 nM.

Antimalarial agent 11 (compound 1) is a potent antimalarial agent, a spirocyclic chromane. Antimalarial agent 11 is able to act on D6 (EC50: 1.48 μM) and ARC08-022 (EC50: 1.81 μM).

Antileishmanial agent-14, a sulfuretin analog, exhibits potential activity against Leishmania donovani promastigotes (IC 50 = 4.1 μM) and inhibits infection by L. donovani amastigotes (IC 50 = 11.1 μM) [1].

Antimalarial agent 18, a powerful antimalarial compound characterized by its electronic, highly lipophilic, and siderophoric properties, falls within the acyloxymethyl series, acting as a fosmidomycin surrogate. It effectively inhibits the non-mevalonate isoprenoid biosynthesis pathway by targeting the IspC enzyme. This compound demonstrates significant inhibitory activity against P. falciparum (IC50 = 50 nM) and A. baumanii (IC50 = 390 nM).

Antimalarial agent 19 (compound 6e) exhibits antimalarial activity against the blood stages of P. falciparum K1 and P. berghei, with EC50 values of 0.3 µM and 15.3 µM, respectively. It demonstrates good aqueous solubility, intestinal permeability, and microsomal stability relative to gamhepathiopine [1].

Anti-inflammatory agent 14 (compound 28) has a MIC 50 of 2 μM for Mtb H37Rv. Anti-inflammatory agent 14 is also an anti-inflammatory agent [1].